Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT: RGX-314 gene therapy vs anti-VEGF in neovascular AMD
2023-503666-23-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Feb 2024
- Modality
- Gene Therapies
- Countries
- 10
01
Overview
Phase 3, randomised, single-blind trial of surabgene lomparvovec in exudative macular degeneration (2 arms), sponsored by AbbVie Inc. Primary endpoint: Primary: Mean change from baseline in BCVA to Week 54 (ETDRS). Planned start Feb 2024; status: authorised.
02
Drugs
surabgene lomparvovec
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2023-503666-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503666-23-00.